BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Clinical trials for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for pancreatic cancer: study tests Cutting-Edge therapies
Disease control TerminatedThis study aimed to test new treatments for people with pancreatic cancer that hasn't spread. It was designed for three groups: those whose tumors can be removed by surgery, those where it's borderline, and those with advanced local disease. The goal was to see if new therapies w…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:21 UTC
-
Could a common blood pressure drug boost radiation against tough pancreatic tumors?
Disease control OngoingThis early-phase study tests whether adding the blood pressure drug losartan to a shorter, stronger course of radiation can help treat pancreatic cancer that is either hard to remove surgically or has spread nearby. Losartan may improve blood flow and oxygen in the tumor, making …
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Experimental pancreatic cancer combo trial halted midway
Disease control TerminatedThis early-stage study tests a new drug called NBTXR3, which is activated by radiation, for people with pancreatic cancer that is locally advanced or borderline resectable. The goal is to find a safe dose and see if it helps control the tumor. The trial was suspended and enrolled…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
Promising cocktail targets pancreatic tumors before surgery
Disease control OngoingThis study tests a combination of chemotherapy (gemcitabine, nab-paclitaxel) and two immunotherapy drugs (durvalumab, oleclumab) given before surgery to people with pancreatic cancer that can be removed. The goal is to shrink the tumor and improve the body's immune response. Abou…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC